Performances
Health issues
Join us
Since December 2015, Pharma 5 Laboratory has launched the first 100% Moroccan “SSB® 400” anti-hepatitis C drug based on Sofosbuvir.
This drug belongs to a new generation of direct-acting antivirals that allows the care and definitive treatment, at low cost, of more than 625,000.00 people suffering from hepatitis C in Morocco. The accessibility to this revolutionary drug also makes it possible today to envisage the total eradication of hepatitis C in the Kingdom, in accordance with the objectives and ambitions of the National Health Authorities.
In March 2016 (3 months after the launch of SSB® 400), Pharma 5 continued its commitment to the fight against hepatitis C in Morocco by launching the marketing of complementary treatments necessary for the total, rapid and effective management of the main hepatitis C genotypes registered in Morocco.
SSB® 400
Sofosbuvir
The marketing of the SSB® 400 is a major national and regional first, it was made possible by an exemplary public-private partnership between the Ministry of Health and the PHARMA 5 laboratory.
The SSB® 400 is marketed at a price of MAD 3,000.00 per box, which is the lowest cost of introduction internationally. By way of comparison, the cost of the 12-week cure is MAD 451,000.00 in France and MAD 800,000.00 in the United States. In Morocco, the price of the 12-week cure will be MAD 9,000.00 for SSB® 400 and shall allow the virological cure of more than 90% of hepatitis C patients.
The accessibility of this revolutionary drug makes it possible to envisage the total eradication of hepatitis C in the Kingdom, in accordance with the objectives and ambitions of the national health authorities. In an effort to make this drug accessible to the greatest number of Moroccan patients, PHARMA 5 has also introduced SSB® 400 to the list of drugs eligible for reimbursement.
Dakasvir® et Rivabir®
Daclatasvir and Ribavirine
Complementary treatments, Dakasvir® and Rivabir®, 100% Moroccan, such as SSB® 400, have many advantages for the Moroccan patient.
First of all, they are economically more accessible to the largest number of people: a box of Daclatasvir® costs MAD 100,000.00 in Europe compared to MAD 1,549.00 for a box of Dakasvir®.
Combinations of Sofosbuvir and/or Daclatasvir and/or Ribavirin then make it possible to obtain a 95% cure rate, compared to 50% with previous treatments, for hepatitis C genotypes 1 and 2, which account for 99% of viral infections in Morocco. These complementary treatments present another important argument: their low toxicity rate. In fact, the use of these complementary medicines is accompanied by very few side effects, unlike the old complementary treatments.
In October 2017, Pharma 5 launched “Tefovir® Pharma 5”: the first 100% Moroccan generic hepatitis B treatment.
Based on Tenofovirdisoproxilfumarate, Tefovir® Pharma 5 is indicated for the treatment of chronic hepatitis B in adult patients and adolescents 12 to less than 18 years of age.
This new drug is available throughout the national territory at a price 10 times cheaper than the original drug (less than MAD 300.00 per box) and in compliance with the most demanding international quality, safety and efficacy standards.
Tefovir® Pharma 5
Ténofovir disoproxil fumarate
The new drug responds to the same issues and needs expressed at the time of launching SSB® 400. In addition to being particularly expensive (more than MAD 3,000,000 per month), the original drug is not marketed in Morocco. Patients were therefore forced to obtain it abroad or to undergo combinations of alternative molecules, which are not very effective and have significant side effects.
Based on Tenofovirdisoproxilfumarate, Tefovir® Pharma 5 is indicated for the treatment of chronic hepatitis B in adult patients and adolescents 12 to less than 18 years of age.
This new drug is available throughout the country at a price 10 times cheaper than any princeps (less than MAD 300 a box) and in compliance with the most demanding international quality, safety and efficacy standards.
“Thanks to the pertinence of these very encouraging results and the relevance of its approach to galenic research and development, the PHARMA 5 laboratory is continuing its commitment to making available the largest possible number of latest generation, reliable and accessible treatments to treat all forms of hepatitis. However, we insist on the crucial importance of screening operations that allow better diagnosis of patients and better protection of their entourage. To date, only 1 in 100 people in Morocco know that they are infected with hepatitis C.”, concludes Myriam Lahlou Filali, Managing Director of the PHARMA 5 Group.